Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Calendars
Economic Indicators
Calculators
Education
About Us
Working with TipRanks
Follow Us
Inovio Pharmaceuticals (INO)
NASDAQ:INO
RESEARCH TOOLSreports
Holding INO?
Track your performance easily
INO Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$3.90 - $14.75
Previous Close$5.67
Volume198.51K
Average Volume (3M)297.17K
Market Cap
$145.40M
Enterprise Value$47.96M
Total Cash (Recent Filing)$110.42M
Total Debt (Recent Filing)$12.98M
Price to Earnings (P/E)―
Beta2.08
Next Earnings
Nov 05, 2024EPS Estimate
-$1.15Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-5.11
Shares Outstanding25,964,268
10 Day Avg. Volume227,696
30 Day Avg. Volume297,166
Standard Deviation0.29
R-Squared0.02
Alpha0.00164
Financial Highlights & Ratios
Price to Book (P/B)1.52
Price to Sales (P/S)245.67
Price to Cash Flow (P/CF)-1.30
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/Revenue81.02
Enterprise Value/Gross Profit57.64
Enterprise Value/Ebitda-0.56
Forecast
1Y Price Target
$17.50Price Target Upside214.75% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering4
Inovio Pharmaceuticals News
Bulls Say, Bears Say
Bulls Say
Drug ApprovalINO-3107 has been granted Breakthrough Therapy designation and is likely qualified for priority review.
Innovative MedicineINO-3107 may be the first non-surgical DNA medicine approved for the treatment of Recurrent Respiratory Papillomatosis (RRP).
Regulatory ProgressINO-3107 gains the UK's Innovation Passport designation, supporting optimism around its path to market.
Bears Say
EarningsNet loss totaled $32.2M in 2Q24.
Financial PerformanceNet loss in 1Q24 was $30.5M, higher than the estimated loss of $27.0M.
Project DelaysINO-3107 BLA submission delayed to mid-2025 due to a device-related issue.
---
Ownership Overview
0.85% Insiders
8.66% Mutual Funds
0.13% Other Institutional Investors
80.14% Public Companies and Individual Investors
Risk Analysis
Main Risk Category
Finance & CorporateFinancial and accounting risks. Risks related to the execution of corporate activity and strategy
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
INO FAQ
What was Inovio Pharmaceuticals’s price range in the past 12 months?
Inovio Pharmaceuticals lowest stock price was $3.90 and its highest was $14.75 in the past 12 months.
What is Inovio Pharmaceuticals’s market cap?
Currently, no data Available
When is Inovio Pharmaceuticals’s upcoming earnings report date?
Inovio Pharmaceuticals’s upcoming earnings report date is Nov 05, 2024 which is in 7 days.
How were Inovio Pharmaceuticals’s earnings last quarter?
Inovio Pharmaceuticals released its earnings results on Aug 08, 2024. The company reported -$1.19 earnings per share for the quarter, missing the consensus estimate of -$1.102 by -$0.088.
Is Inovio Pharmaceuticals overvalued?
According to Wall Street analysts Inovio Pharmaceuticals’s price is currently Undervalued.
Does Inovio Pharmaceuticals pay dividends?
Inovio Pharmaceuticals does not currently pay dividends.
What is Inovio Pharmaceuticals’s EPS estimate?
Inovio Pharmaceuticals’s EPS estimate is -$1.15.
How many shares outstanding does Inovio Pharmaceuticals have?
Inovio Pharmaceuticals has 25,964,268 shares outstanding.
What happened to Inovio Pharmaceuticals’s price movement after its last earnings report?
Inovio Pharmaceuticals reported an EPS of -$1.19 in its last earnings report, missing expectations of -$1.102. Following the earnings report the stock price went down -3.1%.
Which hedge fund is a major shareholder of Inovio Pharmaceuticals?
Among the largest hedge funds holding Inovio Pharmaceuticals’s share is Graham Capital Management, L.P.. It holds Inovio Pharmaceuticals’s shares valued at 103K.
---
Inovio Pharmaceuticals Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$17.50 (214.75% Upside)
$17.50 (214.75% Upside)
Blogger Sentiment
Bullish
INO Sentiment 100%
Sector Average 71%
Sector Average 71%
Hedge Fund Trend
Increased
By 12.7K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Negative
Last 7 Days ▼ 1.5%
Last 30 Days ▼ 3.5%
Last 30 Days ▼ 3.5%
Technicals
SMA
Negative
20 days / 200 days
Momentum
28.62%
12-Months-Change
Fundamentals
Return on Equity
-91.42%
Trailing 12-Months
Asset Growth
-42.59%
Trailing 12-Months
Company Description
Inovio Pharmaceuticals
Inovio Pharmaceuticals, Inc. is a late-stage biotechnology company, which engages in the discovery, development, and commercialization of DNA-based immunotherapies and vaccines. Its drug candidates include SynCon immunotherapies which helps break the immune system's tolerance of cancerous cells; and CELLECTRA delivery system which facilitates optimized cellular uptake of the SynCon immunotherapies. The company was founded by David B. Weiner on June 29, 1983 and is headquartered in Plymouth Meeting, PA.
---
INO Earnings Call
Q2 2024
0:00 / 0:00
---
INO Stock 12 Month Forecast
Average Price Target
$17.50
▲(214.75% Upside)
Technical Analysis
Best Analysts Covering INO
1 Year
1 Year Success Rate
0/5 ratings generated profit
1 Year Average Return
-38.00%
reiterated a buy rating 3 months ago
Copying Roy Buchanan's trades and holding each position for 1 Year would result in 0.00% of your transactions generating a profit, with an average return of -38.00% per trade.
---